TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
To date, immune checkpoint inhibitors have been successively approved and widely used in clinical cancer treatments, however, the overall response rates are very low and almost all cancer patients eventually progressed to drug resistance, this is mainly due to the intricate tumor microenvironment an...
Main Authors: | Hui Qiu, Zhiying Shao, Xin Wen, Jinghua Jiang, Qinggong Ma, Yan Wang, Long Huang, Xin Ding, Longzhen Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.716710/full |
Similar Items
-
Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression
by: Margaret A. McBride, et al.
Published: (2021-02-01) -
Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
by: Vera Petrova, et al.
Published: (2020-03-01) -
Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma
by: Tietze Stefanie, et al.
Published: (2021-04-01) -
TREM2 regulates innate immunity in Alzheimer’s disease
by: Jiang-Tao Li, et al.
Published: (2018-04-01) -
Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker
by: Xin Cheng, et al.
Published: (2021-02-01)